Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Multiple Myeloma 2Breast Neoplasms 2Uterine Cervical Dysplasia 1Sarcoma 1Polycystic Ovary Syndrome 1Peripheral Nervous System Diseases 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Leukemia 1Insulin Resistance 1Diabetes Mellitus 1Central Nervous System Neoplasms 1Cardiovascular Diseases 1Cardiotoxicity 1Burns 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Fenofibrate × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡